The DOI matches its Crossref record.
Thalidomide in the treatment of lepra reactions
Abstract
In 6 consecutive cases of lepromatous leprosy, acute severe lepra reactions were qUickly resolved with disappearance of symptoms as well as signs after the use of thalidomide as a sedative. No exceptions were noted. Concurrent therapy with sulfones and arsenicals did not appear to be involved. The cases are reported at this early stage because of the obvious importance of corroborating these findings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Thalidomide is an inhibitor of angiogenesis.
D'Amato, R. J., Loughnan, M. S., Flynn, E., & Folkman, J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.4082 · Cited by 2,454
Identification of a Primary Target of Thalidomide Teratogenicity
Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H. (2010) · Science · doi:10.1126/science.1177319 · Cited by 2,136
Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide
Fischer, E. S., Böhm, K., Lydeard, J. R., Yang, H., Stadler, M. B., Cavadini, S., Nagel, J., Serluca, F., Acker, V., Lingaraju, G. M., et al. (2014) · Nature · doi:10.1038/nature13527 · Cited by 1,141
The Continuing Challenges of Leprosy
Scollard, D. M., Adams, L. B., Gillis, T. P., Krahenbuhl, J. L., Truman, R. W., & Williams, D. L. (2006) · Clinical Microbiology Reviews · doi:10.1128/cmr.19.2.338-381.2006 · Cited by 928
Thalidomide-induced Teratogenesis: History and Mechanisms
Vargesson, N. (2015) · Birth Defects Research Part C Embryo Today Reviews · doi:10.1002/bdrc.21096 · Cited by 912
The evolution of thalidomide and its IMiD derivatives as anticancer agents
Bartlett, J. B., Dredge, K., & Dalgleish, A. G. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1323 · Cited by 809
Thalidomide: The Tragedy of Birth Defects and the Effective Treatment of Disease
Kim, J. H., & Scialli, A. R. (2011) · Toxicological Sciences · doi:10.1093/toxsci/kfr088 · Cited by 659
Haslett, P. A. J., Corral, L. G., Albert, M., & Kaplan, G. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.11.1885 · Cited by 573
Muscle wasting and cachexia in heart failure: mechanisms and therapies
von Haehling, S., Ebner, N., dos Santos, M. R., Springer, J., & Anker, S. D. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.51 · Cited by 421
Cardiac cachexia: A systematic overview
von Haehling, S., Lainscak, M., Springer, J., & Anker, S. D. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.09.009 · Cited by 348
Amino-substituted thalidomide analogs: Potent inhibitors of TNF-α production
Muller, G. W., Chen, R., Huang, S.-Y., Corral, L. G., Wong, L. M., Patterson, R. T., Chen, Y., Kaplan, G., & Stirling, D. I. (1999) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(99)00250-4 · Cited by 341
Thalidomide: current and potential clinical applications
Calabrese, L., & Fleischer, A. B. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00408-8 · Cited by 324
Zhu, Y. X., Kortuem, K. M., & Stewart, A. K. (2013) · Leukemia & Lymphoma · doi:10.3109/10428194.2012.728597 · Cited by 293
Advancing host-directed therapy for tuberculosis
Wallis, R. S., & Hafner, R. (2015) · Nature Reviews Immunology · doi:10.1038/nri3813 · Cited by 291
Mchugh, S. M., Rifkin, I. R., Deighton, J., Wilson, A. B., Lachmann, P. J., Lockwood, C. M., & Ewan, P. W. (2008) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.1995.tb05527.x · Cited by 263
Multispecific drugs herald a new era of biopharmaceutical innovation
Deshaies, R. J. (2020) · Nature · doi:10.1038/s41586-020-2168-1 · Cited by 262
Mechanism of action in thalidomide teratogenesis
Stephens, T. D., Bunde, C. J. W., & Fillmore, B. J. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00388-3 · Cited by 259
Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience
Holstein, S. A., & McCarthy, P. L. (2017) · Drugs · doi:10.1007/s40265-017-0689-1 · Cited by 255
Melchert, M., & List, A. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.01.022 · Cited by 246
Muller, G. W., Corral, L. G., Shire, M. G., Wang, H., Moreira, A., Kaplan, G., & Stirling, D. I. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm9603328 · Cited by 158
Clinical pharmacokinetics of thalidomide
Teo, S. K., Colburn, W. A., Tracewell, W. G., Kook, K. A., Stirling, D. I., Jaworsky, M. S., Scheffler, M. A., Thomas, S. D., & Laskin, O. L. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443050-00004 · Cited by 150
Advances in targeted degradation of endogenous proteins
Röth, S., Fulcher, L. J., & Sapkota, G. P. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03112-6 · Cited by 92
Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs
Ito, T., & Handa, H. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-2073-4 · Cited by 84
Recent advances in the molecular mechanism of thalidomide teratogenicity
Gao, S., Wang, S., Fan, R., & Hu, J. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110114 · Cited by 78
The application and biology of immunomodulatory drugs (IMiDs) in cancer
Pan, B., & Lentzsch, S. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.07.004 · Cited by 76
Metadata
- Authors
- Sheskin, J.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 1965-05
- Volume
- 6
- Issue
- 3
- Pages
- 303-306
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2336461395
- Cited by
- 533
- References
- 0
- FWCI
- 9.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.